Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals

Mirum Pharmaceuticals MIRM has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $53.25, a high estimate of $72.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 1.43% increase from the previous average price target of $52.50.

Diving into Analyst Ratings: An In-Depth Exploration

In examining recent analyst actions, we gain insights into how financial experts perceive Mirum Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mirum Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Mirum Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Mirum Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Mirum Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Mirum Pharmaceuticals Better

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

A Deep Dive into Mirum Pharmaceuticals's Financials

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Over the 3 months period, Mirum Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 45.74% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Mirum Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -47.66%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Mirum Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -12.74%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Mirum Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of -5.12%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Mirum Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.22. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.